CL2020003374A1 - Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad - Google Patents

Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad

Info

Publication number
CL2020003374A1
CL2020003374A1 CL2020003374A CL2020003374A CL2020003374A1 CL 2020003374 A1 CL2020003374 A1 CL 2020003374A1 CL 2020003374 A CL2020003374 A CL 2020003374A CL 2020003374 A CL2020003374 A CL 2020003374A CL 2020003374 A1 CL2020003374 A1 CL 2020003374A1
Authority
CL
Chile
Prior art keywords
anxiety
tept
cannabinoids
treat
composition
Prior art date
Application number
CL2020003374A
Other languages
English (en)
Inventor
Harry Karelis
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of CL2020003374A1 publication Critical patent/CL2020003374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden ?9-tetrahidrocannabinol (THC), cannabidiol (CBD) y una fracción terpénica obtenida mediante la extracción de una planta de cannabis, y su utilización en el tratamiento de la ansiedad y/o el trastorno de estrés postraumático (TEPT).
CL2020003374A 2018-07-03 2020-12-23 Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad CL2020003374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2018100925A AU2018100925A4 (en) 2018-07-03 2018-07-03 Cannabinoid composition and method for treating PTSD and/or anxiety

Publications (1)

Publication Number Publication Date
CL2020003374A1 true CL2020003374A1 (es) 2021-08-13

Family

ID=63079634

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003374A CL2020003374A1 (es) 2018-07-03 2020-12-23 Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad

Country Status (13)

Country Link
US (1) US20210308092A1 (es)
EP (1) EP3817735A4 (es)
KR (1) KR20210071940A (es)
AU (2) AU2018100925A4 (es)
BR (1) BR112020027060A2 (es)
CA (1) CA3104739A1 (es)
CL (1) CL2020003374A1 (es)
CO (1) CO2021001059A2 (es)
IL (1) IL279799A (es)
MX (1) MX2021000024A (es)
PE (1) PE20210974A1 (es)
SG (1) SG11202013235YA (es)
WO (1) WO2020006597A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
WO2023034568A1 (en) * 2021-09-03 2023-03-09 Yale University Specific therapeutic medical marijuana doses for stress and pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP3209312A1 (en) * 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
CA2952335A1 (en) * 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Therapeutic delivery formulations and systems comprising cannabinoids and terpenes
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
EP3630145A4 (en) * 2017-05-31 2021-04-07 Phytecs, Inc. PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM
EP3704263A4 (en) * 2017-10-30 2021-08-25 Endocanna Health, Inc. GRAPHIC USER INTERFACES FOR DETERMINING CUSTOMIZED ENDOCANNABINOID GENOTYPES AND RELATED RECOMMENDATIONS

Also Published As

Publication number Publication date
EP3817735A1 (en) 2021-05-12
EP3817735A4 (en) 2022-03-23
WO2020006597A1 (en) 2020-01-09
KR20210071940A (ko) 2021-06-16
MX2021000024A (es) 2021-05-27
PE20210974A1 (es) 2021-05-25
CA3104739A1 (en) 2020-01-09
US20210308092A1 (en) 2021-10-07
BR112020027060A2 (pt) 2021-03-30
AU2019297196A1 (en) 2021-01-28
IL279799A (en) 2021-03-01
AU2018100925A4 (en) 2018-08-09
SG11202013235YA (en) 2021-01-28
CO2021001059A2 (es) 2021-06-30

Similar Documents

Publication Publication Date Title
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
PE20200676A1 (es) Composicion de cannabis
PE20200726A1 (es) Composicion de cannabis
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
MX2019001286A (es) Composicion de cannabis.
CY1123351T1 (el) Χρηση του κανναβιδιολικου οξεος στη θεραπεια της επιληψιας
EP4640275A3 (en) USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME ANXIETY
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
UY37799A (es) Proceso para la purificación y separación de cannabinoides de cáñamo seco y hojas de cannabis
MX2021005474A (es) Plantas con perfil de cannabinoides enriquecido con cannabidiol.
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
CO2017004974A2 (es) Extractos de cannabis y métodos de preparación.
PE20190654A1 (es) Plantas y metodos para aumentar y disminuir la sintesis de cannabinoides
MX2017015083A (es) Composiciones cosmeticas que comprenden e/z-bencilideno-5,6-dimeto xi-3,3-dimetilindan-1-ona.
MX2022012536A (es) Composiciones que comprenden polisacaridos sulfatados.
IN2014DN09507A (es)
MX388770B (es) Composiciones y métodos que usan un polifenol para la salud musculoesquelética.
MX2017004998A (es) Composicion que contiene un extracto o fraccion de una planta del genero justicia.
BR112016017612A2 (pt) Uso de um extrato de uma planta do gênero mentha da família lamiaceae
CO2020000111A2 (es) Composición de gránulos veterinarios que contiene extracto de cáñamo
CO2018014229A2 (es) Composición biopesticida para uso en prevención o minimizacion de la enfermedad de la planta